Table 1.
Patient and disease characteristics and comorbidity at baseline
| Characteristic | TN ≥65 years 420 (n = 27), % |
R/R 420 (n = 67), % |
|---|---|---|
| Median age, years (range) | 71 (65–84) | 66 (37–82) |
| ≥70 years | 74% | 36% |
| ECOG PS | ||
| 0 | 78% | 40% |
| 1 | 22% | 57% |
| 2 | 0% | 3% |
| Rai stage | ||
| 0-II | 41% | 45% |
| III-IV | 56% | 51% |
| Unknown | 4% | 4% |
| Bulky nodes | ||
| >5 cm | 11% | 52% |
| >10 cm | 0% | 9% |
| β2-microglobulin level >3 mg/L | 30% | 42% |
| FISH cytogenetic abnormalities | ||
| Del17p | 7% | 34% |
| Del11q | 0% | 33% |
| Any cytopenia | 67% | 54% |
| Median ANC, 109/L (range) | 4 (0–19) | 2.5 (0–14) |
| ≤1.5 × 109/L | 4% | 27% |
| Median hemoglobin, g/L (range) | 122 (77–157) | 118 (66–176) |
| ≤110 g/L | 37% | 33% |
| Median platelets, 109/L (range) | 113 (32–217) | 107 (29–310) |
| ≤100 × 109/L | 41% | 39% |
| Median CrCl rate, mL/min (range) | 67 (31–114) | 81 (36–213) |
| ≤60 mL/min | 30% | 19% |
| Median prior therapies, n (range) | 4 (1–12) | |
| 1–2 | -- | 31% |
| 3 | 13% | |
| ≥4 | 55% | |
| Type of prior systemic therapy | -- | |
| Chemotherapy | 100% | |
| Nucleoside analog | 94% | |
| Alkylator (including bendamustine) | 90% | |
| Any anti-CD20–based therapy | 99% | |
| Anti-CD20–based chemoimmunotherapy | 97% | |
| Anti-CD52–based therapy (alemtuzumab) | 24% | |
| Idelalisib | 6% |
ANC, absolute neutrophil count; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; R/R, relapsed/refractory; TN, treatment-naïve.